News

October 2, 2020October 2, 2020

FDA Approves Janssen’s Simponi Aria for Juvenile Arthritis Indications

News

The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Simponi Aria (golimumab) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA) in individuals ages 2 ... Read more

October 1, 2020October 1, 2020

FDA Approves Xeljanz for Polyarticular JIA

News

Xeljanz (tofacitinib) has become the first medication in its class to be approved by the U.S. Food and Drug Administration (FDA) as a treatment for polyarticular juvenile idiopathic arthritis (pJIA). ... Read more

September 24, 2020September 24, 2020

Lower Doses of Ilaris Can Maintain Clinical Remission in Systemic-onset JIA, Trial Shows

News

Treatment with Ilaris (canakinumab) at doses lower than the one recommended might be enough to maintain clinical remission in people with systemic juvenile idiopathic arthritis (sJIA), clinical data show. Yet, as ... Read more

September 17, 2020September 17, 2020

Brenzys, Biosimilar to Enbrel, Approved to Treat JIA in Canada

News

Health Canada has expanded the approved use of Brenzys, a biosimilar of Enbrel (etanercept), to include the treatment of juvenile idiopathic arthritis (JIA) and other inflammatory disorders. Brenzys is now indicated ... Read more

September 11, 2020September 11, 2020

Biologics as Initial sJIA Therapy Rising in US, But Glucocorticoids Still in Wide Use

News

Early treatment with biologics is increasingly being given to children newly diagnosed with systemic juvenile idiopathic arthritis (sJIA) in the U.S., but their use varies widely among hospitals and a reliance ... Read more

August 28, 2020August 28, 2020

Nepexto, Biosimilar of Enbrel, Now Available in Germany

News

Nepexto, a biosimilar of Enbrel (etanercept), is now available in Germany for patients with juvenile idiopathic arthritis (JIA) and other inflammatory conditions, according to Lupin Limited and Mylan, the treatment’s developers. “We ... Read more

August 21, 2020August 21, 2020

Humira Shows Long-term Efficacy and Safety in Polyarticular JIA, Phase 3 Trial Reports

News

Long-term treatment with Humira (adalimumab) — reaching through six years — was well-tolerated and effective in children with polyarticular juvenile idiopathic arthritis (JIA), a Phase 3 trial with an extension study ... Read more

August 7, 2020August 7, 2020

JIA Type and Medication Use Affect Longevity of Joint Implants, Study Reports

News

How long implants last in people with juvenile idiopathic arthritis (JIA) who had joint replacement surgery depends on disease type, year of surgery, number of complications, and medication use before and ... Read more

July 24, 2020July 24, 2020

sJIA Patients May Benefit More From Biologics Than Non-systemic, Review Finds

News

Biological therapies or biologics may be more beneficial for young people with systemic juvenile idiopathic arthritis (sJIA) than for those with non-systemic disease, according to a review study. The work ... Read more

July 17, 2020July 17, 2020

Fundraisers and Fun Mark July, Juvenile Arthritis Awareness Month

News

With a goal of dispelling the common notion that only seniors get arthritis, Juvenile Arthritis Awareness Month efforts are underway. The juvenile arthritis community is observing the annual July event, organized by ... Read more